CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 94 filers reported holding CUE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,960 | -31.6% | 19,113 | +8.6% | 0.00% | – |
| Q2 2023 | $64,266 | +29.3% | 17,607 | +26.5% | 0.00% | – |
| Q1 2023 | $49,709 | +23.8% | 13,924 | -1.2% | 0.00% | – |
| Q4 2022 | $40,148 | +29.5% | 14,087 | +0.8% | 0.00% | – |
| Q3 2022 | $31,000 | -91.7% | 13,977 | -90.7% | 0.00% | – |
| Q2 2022 | $374,000 | -49.1% | 150,205 | -0.2% | 0.00% | – |
| Q1 2022 | $735,000 | -57.4% | 150,557 | -1.2% | 0.00% | – |
| Q4 2021 | $1,724,000 | -49.5% | 152,423 | -35.0% | 0.00% | -100.0% |
| Q3 2021 | $3,416,000 | -25.7% | 234,425 | -40.6% | 0.00% | 0.0% |
| Q2 2021 | $4,598,000 | -37.4% | 394,650 | -34.5% | 0.00% | -50.0% |
| Q1 2021 | $7,346,000 | +14.4% | 602,094 | +17.3% | 0.00% | 0.0% |
| Q4 2020 | $6,422,000 | +26.3% | 513,370 | +52.0% | 0.00% | +100.0% |
| Q3 2020 | $5,083,000 | -37.3% | 337,734 | +2.2% | 0.00% | -50.0% |
| Q2 2020 | $8,102,000 | +265.1% | 330,558 | +111.3% | 0.00% | +100.0% |
| Q1 2020 | $2,219,000 | +1409.5% | 156,421 | +1162.3% | 0.00% | – |
| Q2 2018 | $147,000 | – | 12,392 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
| Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
| P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
| Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
| Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
| Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
| Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
| PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
| SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
| Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |